Esbriet achieved a numerical difference in all-cause mortality in three phase 3 trials

All-cause mortality: No statistically significant difference over the study and follow-up period (up to 120 weeks for available patients) 1,14

ASCEND, CAPACITY 004, and CAPACITY 006 exploratory survival analysis vs placebo
Cumulative risk of all-cause mortality through study and follow-up (120 weeks)

HR=hazard ratio; CI=confidence interval.
*No statistically significant difference over the study and follow-up period (up to 120 weeks for available patients).

 

Multinational, randomized, double-blind, placebo-controlled studies vs placebo 1,2

  • Primary FVC endpoint was measured at 52 weeks for ASCEND and at 72 weeks for CAPACITY 004 and CAPACITY 006 1
  • All-cause mortality was assessed over the 120 weeks of the study duration and available follow-up, irrespective of cause of death and whether patients continued treatment after study primary endpoint 1

 

 

EXPERT PERSPECTIVE:
EFFICACY AND SAFETY

Watch Steven Nathan, MD, discuss the clinical efficacy and safety of Esbriet

ESBRIET TABLETS    

Help your patients start and stay on Esbriet with 267 mg and 801 mg tablets 

ESBRIET SAFETY AND TOLERABILITY

Learn more about the safety and tolerability profile of Esbriet